BioSpace News Archive

Week two data of the Barometer study from 5,000 physicians in 30 countries conducted by Sermo reveals the emergence of treatment patterns.

AIVITA Biomedical, Inc., a biotechnology company specializing in innovative cell therapy applications, announced today updated survival data from a year-end analysis of its ongoing Phase 2 clinical trial of AV-GBM-1 in patients with newly diagnosed glioblastoma (GBM). In the analysis, the overall survival rate at both 12 and 1

Aduro, the leader in well-being and performance for organizations and employees, announced today a suite of health, safety and mental well-being solutions designed to support organizations across three operational realities: essential onsite work, remote work, and return-to-work policies and procedures.

As life-saving ventilators grow scarcer worldwide in the fight against COVID-19, an Auburn University research team is racing against the clock to get a device they’ve built into mass production.

Abbott (NYSE: ABT) announced today that the FreeStyle Libre 14 day system, the world’s leading3 continuous glucose monitoring (CGM) technology, can now be used in the hospital setting2 during the COVID-19 pandemic, according to the U.S. Food and Drug Administration (FDA)

AbbVie, a global research and development-based biopharmaceutical company, today announced that the AbbVie CF Scholarship program is now accepting applications for the 2020-2021 academic school year.

As government and private institutions race to develop an effective cure for patients infected by COVID-19, two antimalarial drugs--chloroquine and hydroxychloroquine--have shown some possible potential.

COVID-19 has highlighted the need for countries to rapidly build-up screening and testing infrastructure. In order to address this unprecedented challenge, BGI, in collaboration with the company Etopia, have jointly designed a mobile, inflatable P2 level biosafety laboratory: the “Huo-Yan Air Lab.”

Eurofins, a global leader in testing and laboratory services, announces that Viracor Eurofins, one of the largest and most recognised infectious diseases testing laboratories in the U.S., was granted an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Clinical Diagnostics’ molecular laboratory-developed test (LDT).

With the COVID-19 global pandemic spreading across the country, a Florida firm has pioneered a new way for doctors to securely share all patient records electronically with their staff now working from home.